First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study. [PDF]
Oncol LettCheng L, Chai C, Liu Y, Jiao J.
europepmc +1 more source
Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma. [PDF]
Front PharmacolChen Y +8 more
europepmc +1 more source
Correction to "Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression". [PDF]
Aging Celleuropepmc +1 more source
Related searches:
Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story
Journal of Gastrointestinal Cancer, 2021In recent years, immune-based therapies have emerged as novel pillars for hepatocellular carcinoma (HCC). The rationale of immune-checkpoint inhibitors (ICIs) trial in HCC originated from the fact that the tumor cells and the infiltrating stromal and immune cells promote an immunosuppressive tumor microenvironment, including the up-regulation of immune
Coskun Ozer, Demirtas, Feyza, Gunduz
openaire +2 more sources
Programmed cell death-1 inhibition in lymphoma
The Lancet Oncology, 2015Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells.
Eliza A, Hawkes +2 more
openaire +2 more sources
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could
Xiao-Na, Fang, Li-Wu, Fu
openaire +2 more sources
Targeting Programmed Cell Death 1 in Ovarian Cancer
Journal of Clinical Oncology, 2015Reference EPFL-ARTICLE-216550doi:10.1200/Jco.2015.63.7785View record in Web of Science Record created on 2016-02-16, modified on 2016-08 ...
Homicsko, Krisztian, Coukos, George
openaire +4 more sources
Programmed death‐1 expression in cutaneous B‐cell lymphoma
Journal of Cutaneous Pathology, 2013BackgroundNumbers of programmed death‐1 (PD‐1) positive T cells have prognostic significance in some types of nodal B‐cell lymphomas, but data on PD‐1 expression in cutaneous B‐cell lymphoma (CBCL) are few. In this study we determined the expression and distribution of PD‐1 on neoplastic B cells and reactive T cells in skin sections from primary CBCLs ...
Cetinozman, F. +3 more
openaire +3 more sources
Hodgkin lymphoma (HL) is a lymphoid malignancy characterized by a reactive immune infiltrate surrounding relatively few malignant cells. In this scenario, active immune evasion seems to play a central role in allowing tumor progression. Immune checkpoint inhibitor pathways are normal mechanisms of T-cell regulation that suppress immune effector ...
Jose Caetano, Villasboas +1 more
openaire +2 more sources
Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts
Journal of the American Academy of Dermatology, 2019Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the ...
Wesley Y, Yu +4 more
openaire +2 more sources